CRSP
Price
$46.70
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
4.1B
44 days until earnings call
MRNA
Price
$27.16
Change
-$0.38 (-1.38%)
Updated
Jun 27 closing price
Capitalization
10.5B
32 days until earnings call
Interact to see
Advertisement

CRSP vs MRNA

Header iconCRSP vs MRNA Comparison
Open Charts CRSP vs MRNABanner chart's image
CRISPR Therapeutics AG
Price$46.70
Change-$0.00 (-0.00%)
Volume$32.88K
Capitalization4.1B
Moderna
Price$27.16
Change-$0.38 (-1.38%)
Volume$11.55M
Capitalization10.5B
CRSP vs MRNA Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. MRNA commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and MRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CRSP: $46.70 vs. MRNA: $27.16)
Brand notoriety: CRSP: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 1% vs. MRNA: 103%
Market capitalization -- CRSP: $4.1B vs. MRNA: $10.5B
CRSP [@Biotechnology] is valued at $4.1B. MRNA’s [@Biotechnology] market capitalization is $10.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while MRNA’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 4 bearish.
  • MRNA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +5.54% price change this week, while MRNA (@Biotechnology) price change was +4.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

MRNA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($10.5B) has a higher market cap than CRSP($4.1B). CRSP YTD gains are higher at: 20.655 vs. MRNA (-34.680). CRSP has higher annual earnings (EBITDA): -455.24M vs. MRNA (-3.2B). MRNA has more cash in the bank: 5.98B vs. CRSP (1.86B). CRSP has less debt than MRNA: CRSP (219M) vs MRNA (745M). MRNA has higher revenues than CRSP: MRNA (3.14B) vs CRSP (35M).
CRSPMRNACRSP / MRNA
Capitalization4.1B10.5B39%
EBITDA-455.24M-3.2B14%
Gain YTD20.655-34.680-60%
P/E RatioN/AN/A-
Revenue35M3.14B1%
Total Cash1.86B5.98B31%
Total Debt219M745M29%
FUNDAMENTALS RATINGS
CRSP vs MRNA: Fundamental Ratings
CRSP
MRNA
OUTLOOK RATING
1..100
2661
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
4265
P/E GROWTH RATING
1..100
792
SEASONALITY SCORE
1..100
4250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRNA's Valuation (61) in the Biotechnology industry is in the same range as CRSP (67). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

MRNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as MRNA (96). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.

CRSP's Price Growth Rating (42) in the Biotechnology industry is in the same range as MRNA (65). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CRSP (79). This means that MRNA’s stock grew significantly faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPMRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 17 days ago
84%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NRSH21.720.10
+0.48%
Aztlan NA Nearshoring Stk Sel ETF
GJUL38.550.12
+0.31%
FT Vest U.S. Eq Mod Buffr ETF - Jul
BETZ23.39N/A
N/A
Roundhill Sports Betting & iGaming ETF
LLDR44.44N/A
N/A
Global X Long-Term Treasury Ladder ETF
HYDB47.29-0.04
-0.08%
iShares High Yield Systematic Bond ETF

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+1.69%
BEAM - CRSP
72%
Closely correlated
-1.98%
RXRX - CRSP
71%
Closely correlated
-6.85%
NTLA - CRSP
65%
Loosely correlated
-0.52%
ALLO - CRSP
62%
Loosely correlated
-1.67%
PRME - CRSP
62%
Loosely correlated
-8.68%
More

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with ARCT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
-1.38%
ARCT - MRNA
50%
Loosely correlated
-7.49%
BNTX - MRNA
50%
Loosely correlated
+0.55%
CRSP - MRNA
46%
Loosely correlated
N/A
NVAX - MRNA
45%
Loosely correlated
-1.92%
RGNX - MRNA
45%
Loosely correlated
-4.11%
More